Page last updated: 2024-11-03

propofol and Hamartoma Syndrome, Multiple

propofol has been researched along with Hamartoma Syndrome, Multiple in 1 studies

Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.
propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.

Hamartoma Syndrome, Multiple: A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pancaro, C1
Miller, T1
Dingeman, RS1

Other Studies

1 other study available for propofol and Hamartoma Syndrome, Multiple

ArticleYear
Anesthetic management of a child with Bannayan-Riley-Ruvalcaba syndrome.
    Anesthesia and analgesia, 2008, Volume: 106, Issue:6

    Topics: Anesthetics, Inhalation; Anesthetics, Intravenous; Child; Female; Hamartoma Syndrome, Multiple; Hema

2008